Literature DB >> 31159651

Prevalence of cognitive impairment using the Montreal Cognitive Assessment questionnaire among patients with systemic lupus erythematosus: a cross-sectional study at two tertiary centres in Malaysia.

A Kanapathy1, N R Nik Jaafar1, S S Shaharir2, L F Chan1, M Rozita2, S S Ch'ng3.   

Abstract

INTRODUCTION: Cognitive impairment is a common neuropsychiatric manifestation of systemic lupus erythematosus (SLE). However, it is not routinely assessed for despite its high prevalence and significant disease burden. AIMS: This study aimed to determine the prevalence of mild cognitive impairment (MCI) using the Montreal Cognitive Assessment (MoCA) and its associated factors among patients diagnosed with SLE in Malaysia.
METHODS: A total of 200 SLE patients were recruited prospectively from the outpatient clinics of two tertiary hospitals in Malaysia. Standardized clinical interview was utilized to obtain information on socio-demographic characteristics. All patients were then assessed using the MoCA questionnaire for presence of cognitive impairment; the Patient Health Questionnaire 9 (PHQ-9) for presence of depressive symptoms; and the Wong-Baker Faces Pain Scale (WBFPS) for severity of pain. The evaluation of disease activity and severity were performed by the treating rheumatologists and nephrologists using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics Damage Index (SLICC DI).
RESULTS: The prevalence of MCI was 35%. The significant associated factors from the bivariate analysis were male gender (p = 0.04), educational level (p = 0.00), WBFPS score (p = 0.035) and anticardiolipin IgM (p = 0.01). Further analysis using logistic regression model found that male gender (OR = 7.43, 95% confidence interval 1.06-52.06, p = 0.04), lower educational level (OR = 4.4, 95% confidence interval 1.47-13.21, p = 0.01) and presence of anticardiolipin IgM (OR = 6.81, 95% confidence interval 1.45-32.01, p = 0.031) were associated with impaired MoCA scores. Also, increasing pain scores increased the risk of patients being affected by cognitive impairment.
CONCLUSION: Over one-third of patients with SLE in our cohort were found to have MCI. Risk factors included male gender, lower educational level, higher pain score and presence of anticardiolipin IgM. Physicians are encouraged to perform routine screening to detect cognitive dysfunction in patients with SLE in their clinical practice as part of a more comprehensive management.

Entities:  

Keywords:  Cognitive impairment; Montreal Cognitive Assessment tool; systemic lupus erythematosus

Mesh:

Year:  2019        PMID: 31159651     DOI: 10.1177/0961203319852153

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

1.  Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach.

Authors:  Niels Hansen; Michael Lipp; Jonathan Vogelgsang; Ruth Vukovich; Tristan Zindler; Daniel Luedecke; Stefan Gingele; Berend Malchow; Helge Frieling; Simone Kühn; Johannes Denk; Jürgen Gallinat; Thomas Skripuletz; Nicole Moschny; Jens Fiehler; Christian Riedel; Klaus Wiedemann; Mike P Wattjes; Inga Zerr; Hermann Esselmann; Stefan Bleich; Jens Wiltfang; Alexandra Neyazi
Journal:  Brain Behav Immun Health       Date:  2020-10-01

2.  Cognitive dysfunction among people with systemic lupus erythematosus is associated with reduced participation in daily life.

Authors:  Moon Young Kim; Deepali Sen; Ronald R Drummond; Matthew C Brandenburg; Kathryn Lp Biesanz; Alfred Hj Kim; Seth A Eisen; Carolyn M Baum; Erin R Foster
Journal:  Lupus       Date:  2021-04-01       Impact factor: 2.911

3.  Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review.

Authors:  Sierra Mendelsohn; Lina Khoja; Sofia Alfred; Jennifer He; Melanie Anderson; Denise DuBois; Zahi Touma; Lisa Engel
Journal:  Lupus       Date:  2021-07-15       Impact factor: 2.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.